Literature DB >> 20141709

Distressing sexual problems in United States women revisited: prevalence after accounting for depression.

Catherine B Johannes1, Anita H Clayton, Dawn M Odom, Raymond C Rosen, Patricia A Russo, Jan L Shifren, Brigitta U Monz.   

Abstract

OBJECTIVE: With data from the population-based Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking (PRESIDE) study, which has previously estimated the prevalence of sexual problems and sexually related personal distress in United States women, the prevalence of sexual disorders of desire, arousal, and orgasm was re-estimated, taking concurrent depression into consideration.
METHOD: Current depression was defined in 3 ways as (1) self-reported symptoms alone, (2) antidepressant medication use alone, or (3) symptoms and/or antidepressant use. The unadjusted population prevalence for each distressing sexual problem in the 31,581 respondents was calculated first irrespective of concurrent depression and then in women without concurrent depression, thus determining the size of the population with both conditions present.
RESULTS: The unadjusted population-based prevalence of desire disorder was 10.0% and was reduced to 6.3% for those without concurrent depression, leading to an estimate of 3.7% for those with both conditions present. The same pattern was observed for arousal and orgasm disorders, although overall prevalence estimates were lower.
CONCLUSIONS: Our findings indicate that about 40% of those with a sexual disorder of desire, arousal, or orgasm have concurrent depression, As this study was cross-sectional, causality versus comorbidity cannot be determined. However, our findings stress the importance of evaluating depression along with sexual problems in routine clinical practice and epidemiology research. Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20141709     DOI: 10.4088/JCP.09m05390gry

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  I. Levels of 5α-reduced progesterone metabolite in the midbrain account for variability in reproductive behavior of middle-aged female rats.

Authors:  Alicia A Walf; Jason J Paris; Danielle C Llaneza; Cheryl A Frye
Journal:  Brain Res       Date:  2010-11-09       Impact factor: 3.252

2.  High Prevalence of Sexual Dysfunction in a Vulvovaginal Specialty Clinic.

Authors:  Dina Gordon; Carolyn Gardella; David Eschenbach; Caroline M Mitchell
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

3.  Sexual function and depressive symptoms among female North American medical students.

Authors:  Alan W Shindel; Michael L Eisenberg; Benjamin N Breyer; Ira D Sharlip; James F Smith
Journal:  J Sex Med       Date:  2010-11-03       Impact factor: 3.802

4.  Body image and sexual function in women with polycystic ovary syndrome: a case-control study.

Authors:  Yılda Arzu Aba; Bulat Aytek Şik
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

5.  Sexual Health During COVID-19: A Scoping Review.

Authors:  Nana Ernst Toldam; Christian Graugaard; Rikke Meyer; Louise Thomsen; Sabine Dreier; Emmanuele A Jannini; Annamaria Giraldi
Journal:  Sex Med Rev       Date:  2022-06-30

Review 6.  Sex Differences in the Treatment of Sexual Dysfunction.

Authors:  Veronica Harsh; Anita H Clayton
Journal:  Curr Psychiatry Rep       Date:  2018-03-14       Impact factor: 5.285

Review 7.  Sexual Function Across Aging.

Authors:  Anita H Clayton; Veronica Harsh
Journal:  Curr Psychiatry Rep       Date:  2016-03       Impact factor: 5.285

Review 8.  Pharmacotherapy for Sexual Dysfunction in Women.

Authors:  Jeong Hoo Lee; Jenny E Lee; Veronica Harsh; Anita H Clayton
Journal:  Curr Psychiatry Rep       Date:  2022-02-01       Impact factor: 5.285

9.  Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial.

Authors:  Vahid Farnia; Mehdi Shirzadifar; Jalal Shakeri; Mansour Rezaei; Hafez Bajoghli; Edith Holsboer-Trachsler; Serge Brand
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-09       Impact factor: 2.570

Review 10.  Psychosexual therapy for delayed ejaculation based on the Sexual Tipping Point model.

Authors:  Michael A Perelman
Journal:  Transl Androl Urol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.